Trump Says His Drug Deals Will Save $600 Billion. The Prices Are Still Secret.

New companies announced 9 The White House says nine additional manufacturers joined its most-favored-nation pricing framework.

Claimed market coverage 89% The administration says 26 company agreements now cover this share of the branded-drug market.

Projected savings $600B A 10-year Council of Economic Advisers estimate—not savings already realized from Monday’s deals.

State deadline Sept. 10 State Medicaid programs still have to apply to the voluntary GENEROUS pricing model.

Donald Trump announced Monday that nine additional pharmaceutical manufacturers had agreed to offer American patients and state Medicaid programs prices tied to those paid in other wealthy countries.

If the agreements work as advertised, they could produce a meaningful public benefit.

The United States has a genuine drug-pricing problem. Brand-name medicines cost roughly three times as much here as in selected peer countries even after rebates and discounts, according to the federal analysis underlying the administration’s policy. A government that successfully negotiates lower net prices, improves access to rare-disease treatments and strengthens domestic pharmaceutical manufacturing deserves credit for those results.

But the results are not yet visible in Monday’s announcement.

The White House says its agreements now include 26 manufacturers covering 89% of the branded-drug market and will save approximately $600 billion over ten years. It also says the nine newly announced companies will invest at least $19.6 billion in American manufacturing. Yet the administration did not publish the covered drug list, the prices being replaced, the international benchmark for each product, the discount amounts, a complete roster of participating states or the signed agreements themselves. Reuters reported that the number of drugs and actual discounts remain unclear. One company the White House counted as having a deal—Teva—said it was still in active negotiations.

A confidential rebate can save taxpayers money. It cannot be independently verified until the government publishes the products, participation and results.

What Trump Announced

The White House named Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. It said the agreements apply to medicines used for conditions including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin disorders and several cancers.

The framework has several components.

For existing medicines, participating manufacturers are expected to make selected products available to state Medicaid programs at a “most-favored-nation,” or MFN, net price tied to what other developed countries pay. For future innovative medicines, the administration says manufacturers have committed to launch at comparable prices across the American market. Several companies also agreed to contribute active pharmaceutical ingredients to a strategic federal reserve, and the White House attributed at least $19.6 billion in near-term U.S. manufacturing commitments to the nine-company package.

Those are potentially consequential commitments. Lower Medicaid prices can reduce federal and state spending. Standardized coverage rules can make it easier for manufacturers to offer medicines across many state programs. More domestic production and reserve ingredients can reduce supply-chain vulnerability.

But “agreement” does not describe a single standardized transaction. The public company statements show different scopes, different products, different carve-outs and different stages of completion.

The $600 Billion Number Is a Forecast, Not a Receipt

The administration did publish a methodology for its headline savings estimate. That matters. The $600 billion figure is not simply an unsupported number invented at Monday’s event.

It is also not a measurement of money already saved.

A May report from the White House Council of Economic Advisers estimated approximately $529 billion in ten-year savings from lower prices on drugs launched in the future and another $64.3 billion from applying MFN prices to existing Medicaid medicines. Together, the estimates total about $593.3 billion, which the administration rounds to $600 billion.

The larger portion depends on a model of future drug launches. The CEA applied the proposed policy to FDA novel-drug cohorts from 2021 through 2025, projected pharmaceutical spending forward at 3% annually and assumed that U.S. and foreign net prices would converge enough to produce a 30% reduction in American net prices by the end of ten years. It used the second-lowest adjusted price among a reference group consisting of the G-7 countries other than the United States, plus Denmark and Switzerland.

Those are transparent assumptions. They are not guaranteed outcomes.

Future savings will depend on which medicines launch, when they launch, how manufacturers price them, whether companies maintain the commitments, whether foreign governments accept higher prices and whether Congress eventually turns voluntary arrangements into durable law. The model even assumes that trade pressure will cause some foreign prices to rise as American prices fall.

The Medicaid estimate is conditional as well. The CEA assumed broad implementation across single-source branded drugs and biologics for which current Medicaid net prices exceed the MFN benchmark. It estimated an initial $18 billion annual reduction in drug spending before increased utilization, then assumed greater use of medicines would offset 20% of that amount, leaving a net first-year reduction of approximately $14.4 billion. Savings decline over time as current products lose exclusivity, producing the $64.3 billion ten-year total.

That utilization offset is not necessarily a policy failure. If lower prices allow more Medicaid patients to receive useful treatment, additional use may improve health while reducing the amount saved on the pharmacy ledger.

The essential distinction is this: $600 billion is the administration’s estimate for a fully functioning national framework over a decade. It is not the value of the nine agreements announced Monday, and it is not a balance that has already appeared in federal or household accounts.

Secret Prices Are Normal. Secret Performance Is Not.

Drug-pricing systems routinely rely on confidential rebates. The amount a government program, insurer or pharmacy-benefit manager ultimately pays can be far below the public list price. Publishing every manufacturer’s exact net price could affect negotiations in the United States and violate confidentiality requirements in other countries.

The administration’s own methodology recognizes that problem. It defines MFN using prices net of rebates, discounts and other concessions rather than easy-to-manipulate list prices. Manufacturers report foreign net prices to CMS under a system the government says it can audit.

That is more economically serious than comparing sticker prices.

It also means outsiders cannot reproduce the calculation using public data.

The government can protect commercially sensitive prices without asking the public to accept every claim on faith. CMS can publish the names of covered products, participating states, effective dates, aggregate units, baseline net spending, supplemental rebate totals, utilization changes and realized federal and state savings. It can report ranges or indexed price reductions when exact figures must remain confidential.

None of that requires revealing a foreign country’s proprietary rebate agreement.

Without performance reporting, the public is left with a strange asymmetry: manufacturers and agencies can see the prices, while taxpayers are told only that the result will be historic.

Lower Medicaid Spending Is Not Automatically a Lower Pharmacy Copay

The White House repeatedly describes the agreements as savings “for Americans.” That phrasing combines several different beneficiaries.

The GENEROUS Medicaid model primarily lowers the net amount paid by federal and state governments through supplemental manufacturer rebates. Those savings can protect Medicaid budgets, reduce pressure on taxpayers and allow states to spend more on other health services. Negotiated coverage criteria may also improve patient access to certain medicines.

But the rebate does not necessarily appear as a new discount at the pharmacy counter.

Medicaid already limits prescription-drug copayments to nominal amounts for beneficiaries at or below 150% of the federal poverty level. States may impose different charges for preferred and nonpreferred drugs, and some higher-income beneficiaries can face larger cost sharing, but most Medicaid patients are not paying anything close to a drug’s list price.

Medicaid also already receives substantial statutory rebates. For branded drugs, the basic rebate generally equals the greater of 23.1% of the average manufacturer price or the difference between that price and the manufacturer’s “best price,” plus an additional inflation-related rebate. States may negotiate further supplemental rebates.

The CEA report acknowledges that some Medicaid net prices are already below the proposed international benchmark—or even negative after rebates. The expected savings are therefore concentrated among a smaller group of high-spending single-source products where Medicaid still pays considerably more than peer countries.

That does not make the new discounts unimportant. It means their direct effect is most accurately described as lower government net spending and potentially broader coverage, not a universal reduction in what every Medicaid enrollee pays for a prescription.

Every State Has Access. Not Every State Is Participating.

The White House says every state Medicaid program will have access to the new prices.

CMS describes a more conditional process.

GENEROUS is voluntary for both manufacturers and states. State Medicaid programs have until September 10 to apply. Interested states must obtain the necessary CMS authorization, execute supplemental rebate agreements, align policies with managed-care organizations and implement operational systems. CMS says states can review pricing information and key terms before deciding whether to join.

Manufacturers must also complete applications, negotiate coverage terms with CMS and sign agreements with each participating state. CMS says some earlier manufacturer arrangements enter the model only after certain terms are finalized.

In other words, “available to every state” means every eligible state can pursue the offer. It does not mean every state is already enrolled, every drug is immediately covered or every supplemental rebate is currently being collected.

The September deadlines matter because they separate a national announcement from state-level execution. The administration should publish the final state roster, product coverage and effective dates once participation is complete.

One of the Nine Deals Is Not Final

The clearest discrepancy in Monday’s public record involves Teva.

The White House listed Teva among nine companies with new agreements and included the company in its total of 26 manufacturers.

Teva’s own release was titled as an intent to reach an agreement. It said the company remained in active discussions, described what the arrangement would include “when finalized” and stated that conditions of the negotiations remained confidential. Reuters also reported that Teva was still discussing a potential deal.

A negotiating commitment may be meaningful. Teva has offered active pharmaceutical ingredients for the federal reserve and publicly endorsed the administration’s goals.

It is not the same thing as a completed contract.

That distinction should be reflected in the official count. Based on the public statements available Tuesday morning, the record supports eight newly announced company agreements plus one company describing an active effort to finalize terms—not nine arrangements at an identical stage of completion.

The Company Statements Show That “A Deal” Can Mean Very Different Things

BridgeBio said its voluntary agreement would expand state Medicaid access to its currently marketed medicine through GENEROUS. The company specifically identified Attruby, a treatment for transthyretin amyloid cardiomyopathy, and said it did not expect future pricing mandates for that drug under Medicare Part D. The specific terms remain confidential.

CSL described a broader arrangement. It said current medicines would be offered to Medicaid at prices comparable with other developed countries and newly launched therapies would receive similar treatment across all U.S. payers. CSL also linked the agreement to tariff certainty and a $1.5 billion expansion in Kankakee, Illinois, expected to create at least 300 permanent manufacturing jobs and approximately 800 construction-related jobs.

Those disclosures reveal two important limits on the White House’s top-line statistics.

First, counting a manufacturer does not tell the public how many current drugs are repriced or how much spending is affected. One arrangement may center on a single marketed product; another may cover a broader portfolio and future launches.

Second, the claim that the agreements cover 89% of the branded-drug market should not be read as proof that 89% of current branded-drug spending changed price Monday. The public fact sheet does not define the denominator or explain whether the figure measures company sales, product coverage or another market-share calculation.

The statistic may accurately describe the manufacturers now connected to the framework. It does not, by itself, measure the share of medicines already being purchased at a new price.

The Manufacturing Commitments Could Be Real—But They Need an Additionality Test

The White House says the nine companies committed at least $19.6 billion to near-term American manufacturing. It also identifies specific active pharmaceutical ingredients that UCB, Sun Pharma, Teva and Astellas intend to contribute to a strategic reserve.

Those commitments may provide genuine economic and security benefits. Pharmaceutical supply chains can be vulnerable to foreign production disruptions, and expanding domestic capacity can create specialized construction and manufacturing work.

But an announced investment should be separated into three categories:

• New investment caused by the agreement;
• Previously planned investment accelerated or protected by the agreement; and
• Previously announced spending now included in the administration’s total.

CSL explicitly said its $1.5 billion Illinois project was previously announced and that the new agreements provide additional certainty allowing it to proceed. That may still be valuable. Avoiding a cancellation or delay can preserve jobs and output.

It also means the entire $1.5 billion should not automatically be described as brand-new investment created on Monday.

The same test should be applied across the $19.6 billion total. The administration can substantiate the claim by publishing project locations, prior announcement dates, construction schedules, expected jobs and completed capital spending.

The Strongest Case for Trump

The strongest case for Trump’s policy is substantial.

American brand-name drug prices are exceptionally high. The administration is targeting net prices rather than misleading list prices, using a reference basket that attempts to remove outliers and adjust for national income. Voluntary agreements may avoid some of the litigation and implementation delays that have defeated earlier MFN efforts.

The Medicaid model also attempts to exchange lower prices for more standardized coverage rules. Manufacturers gain a simpler path across participating states; governments gain supplemental rebates; patients may gain access to medicines that states previously restricted because of cost.

The prospective commitment on future launches is potentially more important than discounts on existing products. If broadly honored, it could prevent the United States from continuing to absorb a disproportionate share of global pharmaceutical revenue while other wealthy countries negotiate much lower prices.

And unlike a policy that simply commands a lower sticker price, the framework tries to account for innovation incentives, foreign contributions and domestic manufacturing.

Those features make the program worthy of serious evaluation rather than reflexive dismissal.

They also make transparent evaluation more important.

What Can Be Concluded on September 1

The Bottom Line

The economic disaster is not that Donald Trump negotiated with pharmaceutical companies.

America pays too much for many brand-name medicines. Lowering those prices for Medicaid, cash-paying patients and future drug launches is a legitimate objective. If voluntary agreements produce real rebates, wider access and durable domestic investment, the policy will deserve recognition.

But a serious policy should be able to survive serious measurement.

The administration has announced nine more companies, 89% market coverage, $19.6 billion in investment and $600 billion in savings. The public still does not know how many current medicines changed price, how large the discounts are, which states will participate, when the rebates begin or how one company still negotiating became a completed deal.

The $600 billion estimate is not meaningless. It is a model built from identifiable assumptions.

It is also not money in the bank.

CMS should publish a recurring performance dashboard identifying signed manufacturer status, covered products, participating states, effective dates, units used, aggregate supplemental rebates, changes in access and utilization, patient out-of-pocket effects and realized federal and state savings. The Commerce Department should separately identify which manufacturing projects are new, which were already announced and which milestones have actually been completed.

That reporting would allow the administration to prove its success without exposing every confidential net price.

Until then, Trump’s drug-pricing announcement remains a potentially valuable policy wrapped in numbers the public cannot yet audit.

Lower prices should be celebrated when patients and taxpayers receive them.

A projection should be labeled as a projection.

And a deal should not be counted as finished while one of the companies says it is still negotiating.

Primary Documentation and Reporting

1. White House fact sheet: Nine additional pharmaceutical manufacturers and the MFN framework.
2. Council of Economic Advisers: Savings from Most-Favored-Nation Drug Pricing Policy.
3. Council of Economic Advisers: Full MFN savings methodology.
4. Centers for Medicare & Medicaid Services: GENEROUS Medicaid model.
5. Medicaid.gov: Prescription-drug cost-sharing rules.
6. Medicaid.gov: Medicaid Drug Rebate Program.
7. Reuters: Public details, unresolved discounts and Teva’s negotiating status.
8. Teva: Intent to reach an agreement and active negotiations.
9. BridgeBio: Scope and confidentiality of its voluntary agreement.
10. CSL: Medicaid pricing, future-launch commitments and Illinois manufacturing expansion.

This morning edition was prepared from public information available by 8:25 a.m. Eastern Time on September 1, 2026. It should be updated when CMS publishes the final roster of participating states, the covered-product lists, effective pricing dates or aggregate realized savings, and if Teva announces that its negotiations have been completed.